Enovis Co. (NYSE:ENOV) Shares Acquired by Tributary Capital Management LLC

Tributary Capital Management LLC grew its position in Enovis Co. (NYSE:ENOV) by 33.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 566,089 shares of the company’s stock after acquiring an additional 143,258 shares during the quarter. Enovis comprises about 1.9% of Tributary Capital Management LLC’s holdings, making the stock its 15th largest position. Tributary Capital Management LLC’s holdings in Enovis were worth $24,840,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Pinnacle Bancorp Inc. lifted its holdings in shares of Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after purchasing an additional 371 shares during the period. Aigen Investment Management LP lifted its holdings in shares of Enovis by 5.1% during the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock worth $381,000 after purchasing an additional 430 shares during the period. UMB Bank n.a. lifted its holdings in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the period. Finally, FMR LLC lifted its holdings in Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after acquiring an additional 484 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on ENOV shares. Evercore ISI reduced their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. JMP Securities started coverage on Enovis in a report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and a consensus target price of $65.86.

Enovis Stock Performance

Shares of ENOV stock opened at $47.78 on Friday. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The business has a fifty day simple moving average of $45.93 and a 200-day simple moving average of $44.45. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. During the same quarter last year, the business posted $0.56 earnings per share. The business’s revenue for the quarter was up 21.0% on a year-over-year basis. On average, analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.